What is Non-Invasive Prenatal Testing (NIPT)?
Non-Invasive Prenatal Testing (NIPT) is a screening method that analyzes cell-free fetal DNA circulating in the mother’s bloodstream to detect certain genetic conditions in the fetus. Unlike traditional invasive procedures such as amniocentesis or chorionic villus sampling, NIPT poses no risk to the fetus, as it requires only a simple maternal blood draw.
Introducing PrenatalSAFE® by Eurofins Genoma
PrenatalSAFE® is a state-of-the-art NIPT developed by Eurofins Genoma, designed to identify chromosomal abnormalities with high accuracy. By analyzing fetal DNA from a maternal blood sample, PrenatalSAFE® can detect:
- Common trisomies:
- Trisomy 21 (Down syndrome)
- Trisomy 18 (Edwards syndrome)
- Trisomy 13 (Patau syndrome)
- Sex chromosome aneuploidies:
- Monosomy X (Turner syndrome)
- XXX (Triple X syndrome)
- ΧΧΥ (Klinefelter syndrome)
- ΧΥΥ (Jacobs syndrome)
- Other chromosomal abnormalities, depending on the selected test level.
Key Benefits of PrenatalSAFE®
- Simple: Requires only an 8–10 ml maternal blood sample, collected from the 10th week of gestation.
- Safe: Non-invasive procedure eliminates the risks associated with traditional invasive diagnostic methods.
- Fast: Utilizes high-resolution FAST technology to deliver results in as little as 3 working days.
- Reliable: Offers over 99% sensitivity for detecting chromosomal abnormalities, with a false-positive rate below 0.1%.
- Comprehensive: Capable of detecting chromosomal abnormalities even with low fetal DNA concentrations (as low as 2%).
- Clear Results: Provides definitive outcomes—either positive or negative—for the conditions tested.
Tailored Testing Options
PrenatalSAFE® offers multiple testing levels to suit individual needs:
- PrenatalSAFE® 3: Screens for trisomies 21, 18, and 13.
- PrenatalSAFE® 5: Includes screening for sex chromosome aneuploidies.
- PrenatalSAFE® Plus: Adds analysis for trisomies 9 and 16, and common microdeletion syndromes.
- PrenatalSAFE® Karyo: Provides a genome-wide analysis for chromosomal aneuploidies and structural abnormalities.
- PrenatalSAFE® Complete: Combines Karyo analysis with screening for severe genetic disorders.
- PrenatalSAFE® Full Risk: Includes parental carrier screening for recessive hereditary diseases.
Each testing level is designed to provide comprehensive information, enabling informed decision-making during pregnancy.
Who Should Consider PrenatalSAFE®?
PrenatalSAFE® is suitable for all pregnant women from the 10th week of gestation, including:
- Singleton or twin pregnancies conceived naturally or via assisted reproductive technologies.
- Women with advanced maternal age (>35 years).
- Couples with advanced paternal age (>40 years).
Cases where invasive testing is contraindicated.
Prenatal Checkup
Dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernaturaut odit aut fugit, sed quia consequuntur.